French diabetes drug request passes FDA in US

2nd March 2005, Comments 0 comments

PARIS, March 2 (AFP) - The US Food and Drug Administration has accepted a new drug application by French pharmaceutical group Sanofi-Aventis and Pfizer of the United States for Exubera, a dry powder form of insulin that is inhaled into the lungs prior to eating, the companies said Wednesday.

PARIS, March 2 (AFP) - The US Food and Drug Administration has accepted a new drug application by French pharmaceutical group Sanofi-Aventis and Pfizer of the United States for Exubera, a dry powder form of insulin that is inhaled into the lungs prior to eating, the companies said Wednesday.

The companies want to provide Exubera to adult patients with type 1 (the most serious) and type 2 diabetes, a joint statement said.

Exubera is currently also under review by the European Medicines Evaluation Agency.

The treatment has been tested on more than 3,400 patients, some for more than seven years, the statement said.

"It is estimated that nearly 180 million people worldwide suffer from diabetes, and the number is expected to rise to 300 million people in the next 20 years," it added.

Diabetes and associated complications cost more than USD 100 million (EUR 75 million) per year in the US, the drug companies said.

© AFP

Subject: French News

0 Comments To This Article